An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Graceway Pharmaceuticals, LLC84 enrolled

Overview

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Warts

Interventions

ResiquimodDRUG

Eligibility

Sex: ALLMin age: 3 YearsMax age: 11 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of common wart(s) * Ages between 3 to 11 Exclusion Criteria: * Other types of wart(s), ie. plantar * Currently participating in another clinical study * Chronic viral hepatitis B or C

Locations (10)

Arkansas

Fayetteville, Arkansas, United States

Arkansas

Little Rock, Arkansas, United States

Georgia

Newnan, Georgia, United States

Illinois

Buffalo Grove, Illinois, United States

Outcomes

Primary Outcomes

Clearance of treated common wart(s)

Secondary Outcomes

Partial clearance of treated common wart(s)

Wart recurrence

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.